Valo, Novo Nordisk

Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).
Novo Nordisk expands drug collaboration with Valo Health
Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop novel treatments for obesity, type-2 diabetes, and cardiovascular disease. It has committed to a near-term payment of $190 million and the collaboration expects milestone payments of approximately $4.
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular diseaseExpanded collaboration includes near-term payments totalling up to 190 million US dollars,
Novo Nordisk Expands Drug Discovery Collaboration With Valo Health For Cardiometabolic Diseases
Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, conducting trials, and developing therapeutics with human-centric AI small molecule design.
5 Questions Novo Nordisk Needs to Answer to Get Its Stock Moving Higher
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Eli Lilly ( LLY 1.07%) and Novo Nordisk ( NVO -1.99%) are two of the most valuable healthcare stocks in the world, largely ...
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
FierceBiotech3h
Novo Nordisk doubles down on Valo, betting $190M near-term to apply AI to obesity and diabetes
Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...
SchaeffersResearch.com1h
Novo Nordisk Stock Jumps on Upgrade to 'Buy'
U.S.-listed shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are up 3.5% premarket, following a bull note ...
Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone
UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed” ...
Novo Nordisk upgraded at UBS as analysts call CagriSema sell-off "overdone"
Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...
Does Novo Nordisk A/S (NVO) Have an Attractive Valuation?
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...